views

Previously writing on transplant platform company Verici Dx (VRCI), in September with the shares falling to 17.5p I reviewed was the fundraise for accelerated progress or to avert cash crunch ahoy?, concluding continue to avoid. The shares most recently closed at 7.5p, but what of them currently up 20% today on the back of a “CLIA Certificate of Compliance” announcement.

views

Previously writing on transplant platform company Verici Dx (VRCI), in June with the shares down to 26p I questioned was the “fundraise to… continue the accelerated progress” or to avert cash crunch ahoy?. Now half-year results... and the shares currently further down to 17.5p.

views

Previously writing on transplant platform company Verici Dx (VRCI), in March I concluded ‘if the cash is not soon needed, why place now? With the cash burn and a pre-fundraise market cap at even the current 36p share price of above £51 million, avoid’. With a “Commercial Team Appointments” announcement now following results, what do I think now?...

views

Verici Dx (VRCI), a developer of clinical diagnostics for organ transplant, has announced a placing of “at least £10.0 million” at 35p per share, stating it “intends to use the net proceeds of the fundraise to… continue the accelerated progress the company has experienced to date”. So what of currently a 4% share price fall in response?...

NEWSFLOW